ANB032

· AnaptysBio, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ANB032, covering 2025-02-14 to 2025-02-14. Get the full timeline:

Most recent: Clinical Trial Update: This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD). [Phase 2]

See pricing